GlassScriptPhysician profile
Richard A Gan
NPI 1063588481
$13,488.32
in general payments reported to CMS, 2019-2025
60 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,809 · 2020: $2,106 · 2021: $2,242 · 2022: $2,442 · 2023: $2,292 · 2024: $2,493 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,889.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,685.02 | 2019-2024 | Vumerity, Avonex, Tysabri |
| Novartis Pharmaceuticals Corporation | $1,597.45 | 2019-2025 | |
| Abbvie INC. | $1,073.69 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $840.24 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Ucb, INC. | $673.61 | 2019-2024 | Briviact, Rystiggo, Nayzilam |
| Neurocrine Biosciences, INC. | $629.09 | 2019-2024 | Ingrezza, Ongentys |
| Amgen INC. | $408.76 | 2019-2024 | Uplizna |
| Genentech USA, INC. | $408.29 | 2019-2024 | Ocrevus, Enspryng |
| Mdd US Operations, LLC | $365.26 | 2022-2025 | Apokyn, Apokyn, Xadago |
| Eisai INC. | $355.18 | 2019-2024 | |
| Acadia Pharmaceuticals INC | $343.65 | 2019-2024 | Nuplazid |
| Amneal Pharmaceuticals LLC | $334.59 | 2019-2024 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Lilly USA, LLC | $299.62 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Emd Serono, INC. | $274.78 | 2019-2022 | |
| Celgene Corporation | $272.94 | 2020-2024 | Zeposia |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Gan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.